Teva Reports Positive Data from Anti-TL1A Antibody for Inflammatory Bowel Diseases

Image Credit: Adobe Stock Images/doucefleur

Yesterday, Teva Pharmaceuticals announced positive data for its inflammatory bowel diseases (IBD) therapy TEV-’574, an anti-TL1A antibody, at the 2024 European Crohn’s and Colitis Organization (ECCO) Annual Meeting. According to a company press release, the treatment demonstrated promise in providing anti-inflammatory and anti-fibrotic effects, which are essential for treating inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn disease (CD). These findings come amid Teva’s recent agreement with Sanofi to co-develop and co-commercialize TEV-’574 for UC and CD.¹

“These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated. This aligns with our extensive pre-clinical evidence and further supports ongoing clinical investigations of anti-TL1A (TEV-’574) in IBD, where TL1A plays a prominent role in amplification of immune response leading to burdensome inflammation and fibrosis in the gastrointestinal tract,” said Eric Hughes, MD, PhD, EVP, Global R&D, chief medical officer, Teva, in the press release. “We are currently investigating the efficacy and safety of anti-TL1A (TEV-’574) in IBD through the RELIEVE UCCD Phase II trial, which features an innovative and efficient basket study design allowing the inclusion of patients with either type of IBD (ulcerative colitis and Crohn’s disease). These data reinforce the potential for anti-TL1A (TEV-’574) to become a novel treatment option for IBD and solidifies our ongoing commitment to provide innovative medicines to improve the lives of people living with IBD, as quickly as possible.”

Teva and Sanofi first announced their intentions to co-commercialize the treatment back in October. As per terms of the deal, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones, with both companies sharing development costs and net profits/losses in major markets. Upon the beginning of Phase III development and commercialization, Sanofi will take the lead in North America and Asia, while Teva will lead in Europe, Israel, and other specified countries.²

“This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy,” said Richard Francis, Teva CEO and president, in a joint press release. “This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honored to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimize development and global launches.”

References

1. Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting. Teva. February 20, 2024. Accessed February 21, 2024. https://www.tevapharm.com/news-and-media/latest-news/teva-presents-new-data-supporting-safety-tolerability-and-target-engagement-of-anti-tl1a-tev-574-anti/

2. Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment. Sanofi. October 4, 2024. Accessed February 21, 2024. https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-04-05-00-00-2754288